PCSK9 Agents Drug Class Prior Authorization Protocol

Size: px
Start display at page:

Download "PCSK9 Agents Drug Class Prior Authorization Protocol"

Transcription

1 PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics Subcommittee. Drug Requiring Prior Authorization Review: Praluent (alirocumab), Repatha (evolocumab) Formulary Alternative: atorvastatin, ezetimibe Criteria: A. Drug: Praluent 1. Diagnosis: Heterozygous Familial Hypercholesterolemia Criteria: Must meet all of the following requirements: a. Familial hypercholesterolemia (FH) as established by 1 of the following: i. Presence of a mutation in LDLR, apolipoprotein B (ApoB), PCSK9, or ARH adaptor protein (LDLRAP1) gene. ii. Pre-treatment LDL level greater than 190 mg per dl or total cholesterol greater than 290 mg per dl in an adult or pre-treatment LDL level greater than 155 mg per dl or total cholesterol greater than 250 mg per dl in a child and tendo xanthomas in patient or a first-orsecond-degree relative. b. Medical record documentation (e.g. laboratory test results, chart notes) indicating 1 of the following: i. Patient has been adherent for 3 months (90 consecutive days) of highintensity statin therapy and will continue to receive high-intensity statin therapy (e.g. atorvastatin 40 mg or higher, rosuvastatin 20 mg or higher) at the maximally tolerated dose. ii. Patient has been adherent for 3 months (90 consecutive days) of the maximally tolerated statin therapy (e.g. atorvastatin, lovastatin,

2 iii. iv. pravastatin, rosuvastatin, or simvastatin at any dose) and will continue to receive the maximally tolerated dose and patient is unable to tolerate high-intensity statin as evidenced by myalgia (muscle symptoms without CK elevations) or myositis (muscle symptoms with CK elevations less than 10 times ULN). Patient has a labeled contraindication to all statins as documented in medical records. Patient has experienced rhabdomyolysis or muscle symptoms with CK elevations greater than or equal to 10 times ULN. c. Documentation indicating 1 of the following: i. Patient has been adherent for 3 months (90 consecutive days) of Zetia concurrently with the statin. ii. Patient has a labeled contraindication or intolerance to Zetia. d. Documentation indicating 1 of the following treated LDL levels while on a lipid lowering therapy, dated within the last month (30 days): i. LDL greater than or equal to 100 mg per dl with ASCVD. ii. LDL greater than or equal to 130 mg per dl without ASCVD. e. Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, Juxtapid or Kynamro. Specialist: Cardiologist, Endocrinologist or Lipid Specialist Quantity Limit: N/A Duration of Therapy: 6 months (180 days) Reauthorization Criteria: Must meet all of the following requirements: a. Patient is adherent to therapy since the initial authorization. b. Patient continues concurrent use of the high-intensity statin or the statin at the maximally tolerated dose, unless documentation of the inability to take statins is provided. c. Documentation of LDL reduction while on Praluent/Repatha therapy. Duration of Reauthorization: 6 months (180 days) 2. Diagnosis: Clinical Atherosclerotic Cardiovascular Disease Criteria: Must meet all of the following requirements: a. Documentation of 1 of the following: i. Acute Coronary Syndromes. ii. History of Myocardial Infarction (MI) iii. Stable or unstable Angina iv. Coronary or other Arterial Revascularization v. Stroke vi. Transient Ischemic Attack (TIA) vii. Peripheral Arterial Disease presumed to be of Atherosclerotic origin

3 b. Medical record documentation (e.g. laboratory test results, chart notes) indicating 1 of the following: i. Patient has been adherent for 3 months (90 consecutive days) of highintensity statin therapy and will continue to receive high-intensity statin therapy (e.g. atorvastatin 40 mg or higher, rosuvastatin 20 mg or higher) at the maximally tolerated dose. ii. Patient has been adherent for 3 months (90 consecutive days) of the maximally tolerated statin therapy (e.g. atorvastatin, lovastatin, pravastatin, rosuvastatin, or simvastatin at any dose) and will continue to receive the maximally tolerated dose and patient is unable to tolerate high-intensity statin as evidenced by myalgia (muscle symptoms without CK elevations) or myositis (muscle symptoms with CK elevations less than 10 times ULN). iii. Patient has a labeled contraindication to all statins as documented in iv. medical records. Patient has experienced rhabdomyolysis or muscle symptoms with CK elevations greater than or equal to 10 times ULN. c. Documentation indicating 1 of the following: i. Patient has been adherent for 3 months (90 consecutive days) of Zetia concurrently with the statin. ii. Patient has a labeled contraindication or intolerance to Zetia. d. Documentation indicating 1 of the following treated LDL levels while on a lipid lowering therapy, dated within the last month (30 days): i. LDL greater than or equal to 100 mg per dl with ASCVD. ii. LDL greater than or equal to 130 mg per dl without ASCVD. e. Not used in combination with another proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitor, Juxtapid or Kynamro. Specialist: Cardiologist, Endocrinologist or Lipid Specialist Quantity Limit: N/A Duration of Therapy: 6 months (180 days) Reauthorization Criteria: Must meet all of the following requirements: a. Patient is adherent to therapy since the initial authorization. b. Patient continues concurrent use of the high-intensity statin or the statin at the maximally tolerated dose, unless documentation of the inability to take statins is provided. c. Documentation of LDL reduction while on Praluent/Repatha therapy. Duration of Reauthorization: 6 months (180 days) B. Drug: Repatha

4 1. Diagnosis: Homozygous Familial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia. Criteria: Must all of the following requirements: a. Presence of a mutation in LDLR, apolipoprotein B (ApoB), PCSK9, or ARH adaptor protein (LDLRAP1) gene. i. Pre-treatment LDL level greater than 190 mg pr dl or total cholesterol greater than 290 mg per dl in an adult or pre-treatment LDL level greater than 155 mg dl or total cholesterol greater than 250 mg dl in a child and tendo xanthomas in patient or a first-or-second-degree relative. b. Medical record documentation (e.g. laboratory test results, chart notes) indicating 1 of the following: i. Patient has been adherent for 3 months (90 consecutive days) of highintensity statin therapy and will continue to receive high-intensity statin therapy (e.g. atorvastatin 40 mg or higher, rosuvastatin 20 mg or higher) at the maximally tolerated dose. ii. Patient has been adherent for 3 months (90 consecutive days) of the maximally tolerated statin therapy (e.g. atorvastatin, lovastatin, pravastatin, rosuvastatin, or simvastatin at any dose) and will continue to receive the maximally tolerated dose and patient is unable to tolerate high-intensity statin as evidenced by myalgia (muscle symptoms without CK elevations) or myositis (muscle symptoms with CK elevations less than 10 times ULN). iii. Patient has a labeled contraindication to all statins as documented in iv. medical records. Patient has experienced rhabdomyolysis or muscle symptoms with CK elevations greater than or equal to 10 times ULN. c. Documentation indicating 1 of the following: i. Patient has been adherent for 3 months (90 consecutive days) of Zetia concurrently with the statin. ii. Patient has a labeled contraindication or intolerance to Zetia. d. Documentation indicating 1 of the following treated LDL levels while on a lipid lowering therapy, dated within the last month (30 days): i. LDL greater than or equal to 100 mg per dl with ASCVD. ii. LDL greater than or equal to 130 mg per dl without ASCVD. e. Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, Juxtapid or Kynamro. Specialist: Cardiologist, Endocrinologist or Lipid Specialist Quantity Limit: N/A Duration of Therapy: 6 months (180 days) Reauthorization Criteria: Must meet all of the following requirements:

5 a. Patient is adherent to therapy since the initial authorization. b. Patient continues concurrent use of the high-intensity statin or the statin at the maximally tolerate dose, unless documentation of the inability to take statins is provided. c. Documentation of LDL reduction while on Praluent/Repatha therapy. Duration of Reauthorization: 6 months (180 days) 2. Diagnosis: Clinical Atherosclerotic Cardiovascular Disease Criteria: Must meet all of the following requirements: a. Documentation of 1 of the following: i. Acute Coronary Syndromes ii. History of Myocardial Infarction (MI) iii. Stable or unstable Angina iv. Coronary or other Arterial Revascularization v. Stroke. vi. Transient Ischemic Attack (TIA) vii. Peripheral Arterial Disease presumed to be of Atherosclerotic origin b. Medical record documentation (e.g. laboratory test results, chart notes) indicating 1 of the following: i. Patient has been adherent for 3 months (90 consecutive days) of highintensity statin therapy and will continue to receive high-intensity statin therapy (e.g. atorvastatin 40 mg or higher, rosuvastatin 20 mg or higher) at the maximally tolerated dose. ii. Patient has been adherent for 3 months (90 consecutive days) of the maximally tolerated statin therapy (e.g. atorvastatin, lovastatin, pravastatin, rosuvastatin, or simvastatin at any dose) and will continue to receive the maximally tolerated dose and patient is unable to tolerate high-intensity statin as evidenced by myalgia (muscle symptoms without CK elevations) or myositis (muscle symptoms with CK elevations less than 10 times ULN). iii. Patient has a labeled contraindication to all statins as documented in iv. medical records. Patient has experienced rhabdomyolysis or muscle symptoms with CK elevations greater than or equal to 10 times ULN. c. Documentation indicating 1 of the following: i. Patient has been adherent for 3 months (90 consecutive days) of Zetia concurrently with the statin. ii. Patient has a labeled contraindication or intolerance to Zetia. d. Documentation indicating 1 of the following: i. LDL greater than or equal to 100 mg per dl with ASCVD. ii. LDL greater than or equal to 130 mg per dl without ASCVD. e. Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, Juxtapid or Kynamro.

6 Specialist: Cardiologist, Endocrinologist or Lipid Specialist Quantity Limit: N/A Duration of Therapy: 6 months (180 days) Reauthorization Criteria: Must meet all of the following requirements: a. Patient is adherent to therapy since the initial authorization. b. Patient continues concurrent use of the high-intensity statin or the statin at the maximally tolerated dose, unless documentation of the inability to take statins is provided. c. Documentation of LDL reduction while on Praluent/Repatha therapy. Duration of Reauthorization: 6 months (180 days)

7 Clinical Justification: Simon-Broom Diagnostic Criteria Comparison of FDA-Approved Indications Heterozygous familial hypercholesterolemia in adults on maximally tolerated statin therapy who requires additional lowering of LDL. Adjunct to diet modification. Clinical atherosclerotic cardiovascular disease in adults on maximally tolerated statin therapy who requires additional lowering of LDL. Adjunct to diet modification. Homozygous familial hypercholesterolemia in adults on other LDL-lowering therapies who require additional lowering of LDL. Adjunct to diet modification. Praluent (alirocumab) X X Repatha (evolocumab) X X X 2017 American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease For individuals at low risk (i.e., with no risk factors), an LDL-C goal <130 mg/dl is recommended.

8 For individuals at moderate risk (i.e., with 2or fewer risk factors and a calculated 10-year risk of less than 10%), an LDL-C goal <100 mg/dl is recommended. For individuals at high risk (i.e., with an ASCVD equivalent including diabetes or stage 3 or 4 CKD with no other risk factors, or individuals with 2 or more risk factors and a 10- year risk of 10%-20%), an LDL-C goal <100 mg/dl is recommended. For individuals at very high risk (i.e., with established or recent hospitalization for acute coronary syndrome (ACS); coronary, carotid or peripheral vascular disease; diabetes or stage 3 or 4 CKD with 1or more risk factors; a calculated 10-year risk greater than 20%; or heterozygous familial hypercholesterolemia [HeFH]), an LDL-C goal <70 mg/dl is recommended. For individuals at extreme risk (i.e., with progressive ASCVD, including unstable angina that persists after achieving an LDL-C <70 mg/dl, or established clinical ASCVD in individuals with diabetes, stage 3 or 4 CKD, and/or HeFH, or in individuals with a history of premature ASCVD (<55 years of age for males or <65 years of age for females), an LDL-C goal <55 mg/dl is recommended. Atherosclerotic Cardiovascular Disease Risk Categories and LDL-C Treatment Goals 2013 American College of Cardiology/American Heart Association Task Force Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

9 The Expert Panel makes no recommendation for or against specific LDL or non-hdl targets for the primary or secondary prevention of atherosclerotic cardiovascular disease (ASCVD) due to the absence of data on titration of drug therapy to specific goals. Secondary Prevention: High-intensity statin therapy should be initiated or continued as first-line therapy in women and men 75 years of age who have clinical ASCVD, unless contraindicated. Primary Prevention: High-intensity statin therapies are recommended for the following groups with risk 1) Individuals 21 years of age with LDL 190mg/dL; 2) Individuals years of age with diabetes, LDL mg/dl and 7.5% estimated 10-year ASCVD risk; 3) Individuals years of age with LDL mg/dl without clinical ASCVD or diabetes, and with an estimated 10-year ASCVD risk 7.5%. o Moderate-intensity statin therapy for the following groups with risk 1) Individuals years of age with diabetes and LDL mg/dL; 2) Individuals years of age, with LDL mg/dl without clinical ASCVD or diabetes, and with an estimated 10-year ASCVD risk of 5% to <7.5%; 3) Individuals years of age with LDL mg/dl without clinical ASCVD or diabetes, and with an estimated 10-year ASCVD risk 7.5% High-risk patients who have a suboptimal response to statins, who are unable to tolerate a less-than-recommended intensity of a statin, or who are completely statin intolerant, may consider the addition of a non-statin therapy. Intensity of Statin Therapy High-Intensity Statin Therapy Lowers LDL 50% Atorvastatin 40-80mg Rosuvastatin 20-40mg Moderate-Intensity Statin Therapy Lowers LDL by 30-50% Atorvastatin 10-20mg Rosuvastatin 5-10mg Simvastatin 20-40mg Pravastatin 40-80mg Lovastatin 40mg Fluvastatin 80mg Pitavastatin 2-4mg Low-Intensity Statin Therapy Lowers LDL by <30% Simvastatin 10mg Pravastatin 10-20mg Lovastatin 20mg Fluvastatin 20-40mg Pitavastatin 1mg National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP III) 2001

10 Definition of Statin Intolerance, International Lipid Expert Panel 2015 Inability to tolerate at least 2 statins, with at least one started at the lowest starting daily dose. Statin dose reduction is attempted for symptom and biomarker abnormality resolution, rather than discontinuation of statin therapy altogether. Intolerable symptoms or abnormal biomarker changes are reversible upon statin discontinuation, but reproducible by re-challenge of statins; if clinically appropriate. Symptoms or biomarker abnormalities are not attributable to established predispositions such as drug-drug interactions and conditions recognized to increase the risk of statin intolerance such as: hypothyroidism, concurrent illness, significant changes in physical activity/exercise and/or underlying muscle disease. Clinical Studies for Praluent: ODYSSEY Program The efficacy of Praluent was evaluated in five double-blind placebo-controlled studies that enrolled 3499 patients, consisted of 36% patients with heterozygous familial hypercholesterolemia (HeFH) and 54% non-fh with clinical atherosclerotic cardiovascular disease. All patients enrolled were receiving a maximally tolerated statin dose. The Praluent study group received 75mg every 2 weeks followed by criteria-based up-titration to 150mg every 2 weeks at week 12 for patients with suboptimal response. The primary efficacy endpoint, mean percent change in LDL, was measured at week 24. In Study 1 and Study 2, which enrolled both non-fh patients with clinical atherosclerotic cardiovascular disease and HeFH patients, the overall average baseline LDL was 112 mg/dl. At week 24, the treatment differences between Praluent and placebo in mean LDL percentage change were -58% (p <0.0001), and -43% (p <0.0001), respectively.

11 In Study 3, 4 and 5, which exclusively included HeFH patients with overall mean baseline LDL of 170 mg/dl, at week 24, the treatment differences between Praluent and placebo in mean LCL percentage change were -54% (p <0.0001), and -43% (p <0.0001). In the ODYSSEY LONG TERM trial, a randomized trial involving 2341 patients at high risk for cardiovascular events who had LDL of 70 mg/dl or more and were receiving maximum tolerated statin dose, the Praluent group had a lower rate of post hoc cardiovascular events (1.7% vs. 3.3%, HR 0.52, CI ). Adverse effects were similar between Praluent and placebo group (81% vs. 82.5%), as were serious adverse events (18.7% vs. 19.5%). Clinical Studies for Repatha: FOURIER, LAPLACE-2, RUTHERFORD-2, OSLER-1 & OSLER-2 In the FOURIER double-blind, randomized, placebo-controlled trial, 24,564 patients with established cardiovascular disease with LDL-C 70 mg/dl and/or non-hdl-c 100 mg/dl despite high- or moderate-intensity statin therapy received either subcutaneous Repatha (140 mg ever 2 weeks or 420 mg once monthly) or placebo. Most patients were on a high- (69%) or moderate-intensity (30%) statin at baseline, and 5% were also taking ezetimibe. The mean LDL- C at baseline was 98 mg/dl. Repatha significantly reduced the risk for the primary composite endpoint (time to first occurrence of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization; p < ). The difference between the Repatha group and placebo in mean percentage change in LDL-C at week 12 was - 63% (95% CI: -63%,-62%); and at week 72 was -57% (95% CI: -58%,-56%). At week 48, the median LDL-C was 26 mg/dl in the Repatha group. In the LAPLACE-2 multicenter, double-blind, randomized controlled trial, 296 patients with atherosclerotic cardiovascular disease received an open label statin regimen and a 4-week lipid stabilization followed by random assignment to subcutaneous Repatha 140mg every 2 weeks, Repatha 420mg once monthly or placebo for 12 weeks. The mean baseline LDL after 4 weeks of maximum-dose statin therapy was 108 mg/dl. The difference between Repatha group and placebo in mean percentage change in LDL at week 12 was -71% (p< ) and -63% (p< ) for the 140mg every 2 weeks and 420 mg once monthly dosages, respectively. In the RUTHERFORD-2 multicenter, double-blind, randomized placebo-controlled, 12 weektrial, 329 patients with heterozygous familial hypercholesterolemia (HeFH) on statins with or without other lipid lowering therapies were randomized to receive subcutaneous Repatha 140mg every 2 weeks, 420mg once monthly or placebo. The average baseline LDL was 156 mg/dl with 76% of patients on high-intensity statin therapy. The differences between Repatha and placebo in mean percent change in LDL at week 12 was -61% (p< ) and -60% (p< ) for the 140mg every 2 weeks and 420mg once monthly, respectively. In two open-label, randomized trials, OSLER-1 and OSLER-2, 4465 patients who had completed one of twelve phase 2 or phase 3 trials were randomly assigned to Repatha, either 140mg every 2

12 weeks or 420mg monthly plus standard therapy, or standard therapy alone. The study population included those on statin therapy (70%), high-intensity statin therapy (27%), as well as those who were statin-intolerant or who were on no other lipid lowering therapy. The median duration of follow-up was 11.1 months. In contrast to the standard therapy alone, the Repatha study group reduced the LDL by 61% (p< 0.001) from a median of LDL 120mg/dL to 48 mg/dl. The rate of cardiovascular events at 1 year including death, myocardial infarction, unstable angina, coronary revascularization, stroke, transient ischemic attack and heart failure, was reduced from 2.18% on standard therapy alone to 0.95% (p= 0.003, HR 0.47). The risk of adverse events were similar in both groups (69% vs. 64%) as were serious adverse events (7.5% in each group). References: 1.Sabatine MS, Giugliano RP, et al. N Engl J Med. 2015;372(16): Banach M, Rizzo M, Toth PP, et al. Statin intolerance an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015; 11(1): Robinson JG, Farnier M, et al. N Engl J Med. 2015;372(16): Stone NJ, Robinson JG, Lichtenstein AH, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129(25 Suppl 2):S1- S Praluent [Product Information], Tarrytown, NY. Regeneron Pharmaceuticals, Inc. September Repatha [Product Information], Thousand Oaks, CA. Amgen Pharmaceuticals, Inc. December ATP III Final Report PDF. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106: NORD Guides for Physicians. The Physician s Guide to Homozygous Familial Hypercholesterolemia (HoFH): nordphysicianguides.org/homozygous-familialhypercholesterolemia. 12. Cuchel et al. Homozygous familial hypercholesterolemia: new insights and guidance for clinicians to improve detection and clinical management. European Heart Journal: June Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for the management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract 2017; 23: Lloyd-jones DM, Morris PB, Ballantyne CM, et al Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL- Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease

13 Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017; Savaysa [package insert]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; Xarelto [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; Change Control Date Change 02/21/2018 Added quantity limit Updated guidance of 2017 American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,

More information

Drug Class Prior Authorization Criteria PCSK9 Inhibitors

Drug Class Prior Authorization Criteria PCSK9 Inhibitors Drug Class Prior Authorization Criteria PCSK9 Inhibitors Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,

More information

Repatha. Repatha (evolocumab) Description

Repatha. Repatha (evolocumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: September 15, 2017 Repatha Description Repatha

More information

Repatha. Repatha (evolocumab) Description

Repatha. Repatha (evolocumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.16.08 Subject: Repatha Page: 1 of 8 Last Review Date: September 18, 2015 Repatha Description Repatha

More information

Repatha. Repatha (evolocumab) Description

Repatha. Repatha (evolocumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: November 30, 2018 Repatha Description Repatha (evolocumab)

More information

REPATHA (PCSK9 INHIBITORS)

REPATHA (PCSK9 INHIBITORS) REPATHA (PCSK9 INHIBITS) Indications: PCSK9 Inhibitors are indicated for treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease as

More information

Repatha. Repatha (evolocumab) Description

Repatha. Repatha (evolocumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 8 Last Review Date: December 2, 2016 Repatha Description Repatha (evolocumab)

More information

Request for Prior Authorization for PCSK9 inhibitor therapy Website Form Submit request via: Fax

Request for Prior Authorization for PCSK9 inhibitor therapy Website Form  Submit request via: Fax Request for Prior Authorization for PCSK9 inhibitor therapy Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 PCSK9 is a protein that reduces the hepatic removal of low-density

More information

ADMINISTRATIVE POLICY AND PROCEDURE

ADMINISTRATIVE POLICY AND PROCEDURE ADMINISTRATIVE POLICY PROCEDURE Policy #: Subject: PCSK9 INHIBITS (ex: Repatha) Section: Care Management Effective Date: January 1, 2015 Revision Date(s): NA Review Date(s): NA Responsible Parties: Patryce

More information

Praluent. Praluent (alirocumab) Description

Praluent. Praluent (alirocumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.06 Subject: Praluent Page: 1 of 10 Last Review Date: September 20, 2018 Praluent Description Praluent

More information

Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary

Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization

More information

Clinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017

Clinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017 Clinical Policy: (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017 Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: ; Praluent (alirocumab), Repatha (evolocumab) POLICY NUMBER: Pharmacy-61 EFFECTIVE DATE: 8/15 LAST REVIEW DATE: 9/22/2017 If the member s subscriber contract excludes coverage for a specific service

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Repatha) Reference Number: HIM.PA.SP46 Effective Date: 01.01.18 Last Review Date: Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this

More information

Pharmacy Policy Bulletin

Pharmacy Policy Bulletin Pharmacy Policy Bulletin Title: Policy #: PCSK9 inhibitors Rx.01.170 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract.

More information

It is the policy of health plans affiliated with PA Health & Wellness that Vytorin is medically necessary when the following criteria are met:

It is the policy of health plans affiliated with PA Health & Wellness that Vytorin is medically necessary when the following criteria are met: Clinical Policy: Ezetimibe and Simvastatin (Vytorin) Reference Number: PA.CP.PMN.77 Effective Date: 02.01.17 Last Review Date: 07.18 Revision Log Description Ezetimibe/simvastatin (Vytorin ) contains ezetimibe,

More information

4 th and Goal To Go How Low Should We Go? :

4 th and Goal To Go How Low Should We Go? : 4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Proprotein Convertase Subtilisin/kexin type 9 Page 1 of 24 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Proprotein Convertase Subtilisin/kexin type 9 (PCSK9)

More information

Clinical Policy: Evolocumab (Repatha) Reference Number: CP.CPA.269 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Evolocumab (Repatha) Reference Number: CP.CPA.269 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: (Repatha) Reference Number: CP.CPA.269 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

More information

Clinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPA.169 Effective Date:

Clinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPA.169 Effective Date: Clinical Policy: (Repatha) Reference Number: ERX.SPA.169 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Clinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:

Clinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: Clinical Policy: (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Drug Prior Authorization Guideline PCSK9 Inhibitors -

Drug Prior Authorization Guideline PCSK9 Inhibitors - Drug Prior Authorization Guideline PCSK9 Inhibitors - REPATHA (evolocumab) PRALUENT (alirocumab) PA9911 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes-as shown below Additional

More information

Clinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPA.171 Effective Date:

Clinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPA.171 Effective Date: Clinical Policy: (Kynamro) Reference Number: ERX.SPA.171 Effective Date: 01.11.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Vytorin) Reference Number: CP.PMN.77 Effective Date: 02.01.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

PCSK9 Inhibitors DRUG POLICY BENEFIT APPLICATION

PCSK9 Inhibitors DRUG POLICY BENEFIT APPLICATION DRUG POLICY BENEFIT APPLICATION PCSK9 Inhibitors Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions

More information

EVOLOCUMAB Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378

EVOLOCUMAB Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378 Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378 This drug requires a written request for prior authorization. All requests for Repatha (evolocumab) require review by a pharmacist prior

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Evolocumab (Repatha) Reference Number: CP.PHAR.123 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Proprotein Convertase Subtilisin/kexin type 9 Page 1 of 22 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Proprotein Convertase Subtilisin/kexin type 9 (PCSK9)

More information

Subject: Repatha (evolocumab) Original Effective Date: 09/28/2015. Policy Number: MCP-258 Revision Date(s): 5/4/16; 4/17/17

Subject: Repatha (evolocumab) Original Effective Date: 09/28/2015. Policy Number: MCP-258 Revision Date(s): 5/4/16; 4/17/17 Subject: Repatha (evolocumab) Original Effective Date: 09/28/2015 Policy Number: MCP-258 Revision Date(s): 5/4/16; 4/17/17 Review Date(s): 5/4/2016, 4/17/2017, 7/10/2018 DISCLAIMER This Medical Policy

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject PCSK9 Inhibitors Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 9 References... 9 Effective Date... 01/15/2018

More information

PCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia

PCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia PCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia Policy Number: Original Effective Date: MM.04.037 08/01/2016 Line(s) of Business: HMO;

More information

PCSK9 Inhibitors: Promise or Pitfall?

PCSK9 Inhibitors: Promise or Pitfall? PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential

More information

Clinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017

Clinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017 Clinical Policy: (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017 Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.

More information

Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2

Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2 Established CVD Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2 Primary and Secondary Diagnosis Codes Primary Diagnosis: Primary hyperlipidemia

More information

Praluent (alirocumab)

Praluent (alirocumab) Praluent (alirocumab) Policy Number: 5.01.600 Last Review: 06/2018 Origination: 07/2015 Next Review: 06/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Praluent

More information

Clinical Policy: Ezetimibe (Zetia) Reference Number: CP.PMN.78 Effective Date: Last Review Date: 02.19

Clinical Policy: Ezetimibe (Zetia) Reference Number: CP.PMN.78 Effective Date: Last Review Date: 02.19 Clinical Policy: (Zetia) Reference Number: CP.PMN.78 Effective Date: 02.01.17 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Clinical Policy: Alirocumab (Praluent) Reference Number: CP.CPA.268 Effective Date: Last Review Date: 11.17

Clinical Policy: Alirocumab (Praluent) Reference Number: CP.CPA.268 Effective Date: Last Review Date: 11.17 Clinical Policy: (Praluent) Reference Number: CP.CPA.268 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Kynamro) Reference Number: CP.PHAR.284 Effective Date: 10.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

Get a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management

Get a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Alirocumab (Praluent) Reference Number: CP.PHAR.124 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the

More information

High ( 50%) Restrictions mg 20-40mg Simvastatin (Zocor) 10mg 20-40mg $1.66 Pravastatin (Pravachol) mg $6.

High ( 50%) Restrictions mg 20-40mg Simvastatin (Zocor) 10mg 20-40mg $1.66 Pravastatin (Pravachol) mg $6. MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/8/2018 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/17, 5/16, 5/15, 2/14, LOB AFFECTED: Medi-Cal

More information

Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors: PRALUENT (alirocumab) subcutaneous injection REPATHA (evolocumab) subcutaneous injection

Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors: PRALUENT (alirocumab) subcutaneous injection REPATHA (evolocumab) subcutaneous injection REPATHA (evolocumab) subcutaneous injection Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Juxtapid and Kynamro

Juxtapid and Kynamro DRUG POLICY Juxtapid and Kynamro BENEFIT APPLICATION Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions

More information

PCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia

PCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia : 262-267, 2017 Περίληψη Διάλεξης PCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia I. Gouni-Bethold Polyclinic for Endocrinology, Diabetes, and Preventive Medicine University

More information

QUANTITY LIMIT TARGET DRUGS- RECOMMENDED LIMITS Brand (generic) GPI Multisource Code Quantity Limit

QUANTITY LIMIT TARGET DRUGS- RECOMMENDED LIMITS Brand (generic) GPI Multisource Code Quantity Limit Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Criteria- Through Preferred Agent(s) Program Summary This program applies to Commercial, Netresults

More information

Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes

Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for

More information

Repatha (evolocumab) Policy Number: Last Review: 06/2018 Origination: 07/2015 Next Review: 06/2019

Repatha (evolocumab) Policy Number: Last Review: 06/2018 Origination: 07/2015 Next Review: 06/2019 Repatha (evolocumab) Policy Number: 5.01.601 Last Review: 06/2018 Origination: 07/2015 Next Review: 06/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Repatha

More information

Drug Therapy Guidelines

Drug Therapy Guidelines Drug Therapy Guidelines PCSK9 Inhibitors: Praluent TM, Repatha TM Applicable Medical Benefit Effective: 5/1/18 Pharmacy- Formulary 1 x Next Review: 3/19 Pharmacy- Formulary 2 x Date of Origin: 10/9/15

More information

Clinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:

Clinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: Clinical Policy: (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: 01.11.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) INHIBITORS Praluent (alirocumab) Repatha (evolocumab)

PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) INHIBITORS Praluent (alirocumab) Repatha (evolocumab) PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) INHIBITORS Praluent (alirocumab) Repatha (evolocumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the

More information

Patient Lists. Epic ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Please see accompanying full Prescribing Information

Patient Lists. Epic ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Please see accompanying full Prescribing Information ABOUT THIS GUIDE This Guide provides a high-level overview of Patient Lists in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for PRALUENT

More information

What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment?

What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment? What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment? Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center University

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Juxtapid) Reference Number: CP.PHAR.283 Effective Date: 10.01.16 Last Review Date: 08.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this

More information

Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors

Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina at Chapel Hill

More information

Patient List Inquiries

Patient List Inquiries ABOUT THIS GUIDE This Guide provides a high-level overview of Patient List Inquiries in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for

More information

Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors: PRALUENT (alirocumab) subcutaneous injection REPATHA (evolocumab) subcutaneous injection

Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors: PRALUENT (alirocumab) subcutaneous injection REPATHA (evolocumab) subcutaneous injection REPATHA (evolocumab) subcutaneous injection Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Patient Action Sets. Allscripts Touchworks ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION

Patient Action Sets. Allscripts Touchworks ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION ABOUT THIS GUIDE This Guide provides a high-level overview of Patient Action Sets in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for PRALUENT

More information

Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman

Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes

More information

Patient Lists. Allscripts Professional ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION

Patient Lists. Allscripts Professional ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION ABOUT THIS GUIDE This Guide provides a high-level overview of Patient Lists in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for PRALUENT

More information

PCSK9 Inhibitors: Changing the Landscape of Lipid-Lowering Therapy

PCSK9 Inhibitors: Changing the Landscape of Lipid-Lowering Therapy PCSK9 Inhibitors: Changing the Landscape of Lipid-Lowering Therapy http://parriscardio.theangelheartcenter.com/wp-content/uploads/2013/03/heart-disease-prevention.jpg Jennifer Jiang, PharmD PGY1 Pharmacy

More information

High ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ

High ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/16, 5/15, 2/14, 5/12, LOB AFFECTED: Medi-Cal

More information

1. Has this plan authorized this medication in the past for this patient (i.e., previous authorization is on file under this plan)?

1. Has this plan authorized this medication in the past for this patient (i.e., previous authorization is on file under this plan)? 09/07/2016 Prior Authorization AETA BETTER HEALTH OF KETUCK (MEDICAID) PCSK9 Inhibitors (K88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,

More information

What do the guidelines say about combination therapy?

What do the guidelines say about combination therapy? What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,

More information

Lipids & Hypertension Update

Lipids & Hypertension Update Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual

More information

Reports. NextGen ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Please see accompanying full Prescribing Information

Reports. NextGen ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Please see accompanying full Prescribing Information ABOUT THIS GUIDE This Guide provides a high-level overview of in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for PRALUENT (alirocumab)

More information

Learning Objectives. Patient Case

Learning Objectives. Patient Case Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations

More information

Juxtapid (lomitapide)

Juxtapid (lomitapide) Juxtapid (lomitapide) Policy Number: 5.01.599 Last Review: 06/2018 Origination: 07/2015 Next Review: 06/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Juxtapid

More information

New Horizons in Dyslipidemia Management in Primary Care

New Horizons in Dyslipidemia Management in Primary Care New Horizons in Dyslipidemia Management in Primary Care Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or

More information

Cholesterol Management Roy Gandolfi, MD

Cholesterol Management Roy Gandolfi, MD Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians

More information

PCSK9 Inhibitors and Modulators

PCSK9 Inhibitors and Modulators PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s

More information

A New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies

A New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies A New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies BRODY MAACK, PHARMD, BCACP, CTTS Objectives 1. Review current guidelines regarding use of statin medications in the treatment and prevention

More information

No relevant financial relationships

No relevant financial relationships MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu

More information

Educational Objectives. Disease Trajectories and CVD Risk Reduction. Hypercholesterolemia Support for LDL-C Causality

Educational Objectives. Disease Trajectories and CVD Risk Reduction. Hypercholesterolemia Support for LDL-C Causality Educational Objectives At the conclusion of this activity, participants should be able to: Evaluate the extent of residual CVD risk to which ASCVD patients are exposed, and treat additional CVD risk elements

More information

Class Update PCSK9 Inhibitors

Class Update PCSK9 Inhibitors Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease

More information

PCSK9 Inhibitors Current Status

PCSK9 Inhibitors Current Status PCSK9 Inhibitors Current Status Ryan T. Whitney, MD FACC Bryan Heart Fall Conference 2015 Disclosures, Conflicts, and Nefarious Connections I own no stock in the companies mentioned in this talk. I am

More information

Modern Lipid Management:

Modern Lipid Management: Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)

More information

Hyperlipidemia: Past and Present. Rebecca Khaimova, PharmD The Brooklyn Hospital Center

Hyperlipidemia: Past and Present. Rebecca Khaimova, PharmD The Brooklyn Hospital Center Hyperlipidemia: Past and Present Rebecca Khaimova, PharmD The Brooklyn Hospital Center Rkhaimova@tbh.org Conflicts of Interest None to disclose Learning Objectives for Pharmacist Describe the pathophysiology

More information

Reducing Cardiovascular Risk Through Non-Statins. Kim K. Birtcher, PharmD Joseph Saseen, PharmD

Reducing Cardiovascular Risk Through Non-Statins. Kim K. Birtcher, PharmD Joseph Saseen, PharmD Reducing Cardiovascular Risk Through Non-Statins Kim K. Birtcher, PharmD Joseph Saseen, PharmD Target Audience: Pharmacists ACPE#: 0202-0000-18-049-L01-P Activity Type: Application-based This activity

More information

PCSK9 Inhibitors Current Status

PCSK9 Inhibitors Current Status PCSK9 Inhibitors Current Status Ryan T. Whitney, MD FACC Bryan Heart Spring Conference 2016 Disclosures, Conflicts, and Nefarious Connections I own no stock in the companies mentioned in this talk. I am

More information

Novel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy

Novel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,

More information

Kynamro. Kynamro (mipomersen) Description

Kynamro. Kynamro (mipomersen) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.02 Subject: Kynamro Page: 1 of 5 Last Review Date: September 15, 2017 Kynamro Description Kynamro

More information

Lipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute

Lipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute Lipid Guidelines Who, What, and How Low Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute Disclosures! None Objectives! List factors used in screening for dyslipidemia

More information

Registry Processor Reports

Registry Processor Reports ABOUT THIS GUIDE This Guide provides a high-level overview of Registry Processor Reports in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates

More information

Kynamro (mipomersen)

Kynamro (mipomersen) Kynamro (mipomersen) Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 10/01/2015 Current Effective Date: 01/01/201803/01/2019 POLICY A. INDICATIONS The indications below including

More information

New Guidelines in Dyslipidemia Management

New Guidelines in Dyslipidemia Management The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical

More information

Registry Reports. eclinicalworks ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION

Registry Reports. eclinicalworks ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION ABOUT THIS GUIDE This Guide provides a high-level overview of Registry Reports in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for PRALUENT

More information

PCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH

PCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH PCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH Presented by: Michael J. Blaha November 16, 2017 1 Financial Disclosures Grants: Amgen Foundation, Aetna Foundation Advisory Boards: Amgen,

More information

How to Handle Statin Intolerance in the High Risk Patient

How to Handle Statin Intolerance in the High Risk Patient How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl

More information

Approximately 34% of adults in the United States

Approximately 34% of adults in the United States RESEARCH Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia

More information

Lipid Management 2013 Statin Benefit Groups

Lipid Management 2013 Statin Benefit Groups Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date

More information

PCSK9 Inhibitors for Lowering Cholesterol: Ready for Prime Time?

PCSK9 Inhibitors for Lowering Cholesterol: Ready for Prime Time? Original Article Thomas Knickelbine, MD, FACC, FSCCT, FSCAI From: Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN Address for correspondence: Thomas Knickelbine, MD, FACC,

More information

Disclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?

Disclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now? Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl

More information

2/26/19. Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care. Disclosures. Faculty

2/26/19. Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care. Disclosures. Faculty Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care Faculty v Karol E. Watson, MD, PhD Professor of Medicine/Cardiology Co-director, UCLA Program in Preventive Cardiology

More information

Class Update PCSK9 Inhibitors

Class Update PCSK9 Inhibitors Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information